- Record: found
- Abstract: not found
- Article: not found
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti ,
Roger Echols ,
Yuko Matsunaga ,
Mari Ariyasu ,
Yohei Doi ,
Ricard Ferrer ,
Thomas P Lodise ,
Thierry Naas ,
Yoshihito Niki ,
David L Paterson ,
Simon Portsmouth ,
Julian Torre-Cisneros ,
Kiichiro Toyoizumi ,
Richard G Wunderink ,
Tsutae D Nagata
October 2020
October 2020
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d4311659e263">New antibiotics are needed for the treatment of
patients with life-threatening carbapenem-resistant
Gram-negative infections. We assessed the efficacy and safety of cefiderocol versus
best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
</p>